HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“tumor hypoxia generates macrophages that can suppress T cell responses. This suppressive phenotype is mediated by hypoxic induction of arginase 1 and nitric oxide synthase, both that restrict T cell activation. Strikingly, induction of this hypoxic pathway in macrophages is required for optimal tumor growth [84, 85].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, tumor hypoxia and/or HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010), regulatory T-cells (Clambey et al., 2012), and tumor-associated macrophages (Doedens et al., 2010;Imtiyaz et al., 2010) with immunosuppressive functions.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Corzo et al., 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [56]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“Extensive studies in recent years suggested several mechanisms of MDSC-mediated immune suppression that involve arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 2008) and cysteine (Srivastava et al., 2010) metabolism, expression of some surface molecules (Pan et al., 2010), up-regulation…”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationAlmand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationMovahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Cited by
Items 401–500 of 1,000
Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 78
Splenic Hematopoietic and Stromal Cells in Cancer Progression
Steenbrugge, J., Jaeghere, E. A. D., Meyer, E., Denys, H. G., & Wever, O. D. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2339 · Cited by 76
Host B7x Promotes Pulmonary Metastasis of Breast Cancer
Abadi, Y. M., Jeon, H., Ohaegbulam, K. C., Scandiuzzi, L., Ghosh, K., Hofmeyer, K. A., Lee, J. S., Ray, A., Gravekamp, C., & Zang, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202439 · Cited by 69
Cancer-Associated Myeloid Regulatory Cells
Vlaeminck, Y. D., González-Rascón, A. A., Goyvaerts, C., & Breckpot, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00113 · Cited by 81
Hypoxia as a Modulator of Inflammation and Immune Response in Cancer
Castillo‐Rodríguez, R. A., Trejo‐Solís, C., Cabrera‐Cano, A., Gómez‐Manzo, S., & Dávila‐Borja, V. M. (2022) · Cancers · doi:10.3390/cancers14092291 · Cited by 81
Liechtenstein, T., Pérez‐Janices, N., Gato, M., Caliendo, F., Kochan, G. T., Blanco‐Luquin, I., der Jeught, K. V., Vargas, F. A., Guerrero‐Setas, D., Fernández‐Irigoyen, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2279 · Cited by 73
Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition
Curran, C. S., & Keely, P. J. (2012) · Matrix Biology · doi:10.1016/j.matbio.2012.11.016 · Cited by 82
Immune Suppression: The Hallmark of Myeloid Derived Suppressor Cells
Haile, L. A., Greten, T. F., & Korangy, F. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.680635 · Cited by 70
Tian, T., Gu, X., Zhang, B., Liu, Y., Yuan, C., Shao, L., Guo, Y., & Fan, K. (2015) · Cancer Biomarkers · doi:10.3233/cbm-150473 · Cited by 68
Lim, H. X., Hong, H.-J., Cho, D., & Kim, T. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401282 · Cited by 67
Alexander, E. T., Mariner, K., Donnelly, J., Phanstiel, O., & Gilmour, S. K. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1116 · Cited by 78
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
Lewinsky, H., Gunes, E. G., David, K., Radomir, L., Kramer, M. P., Pellegrino, B., Shahor, M. P., Chen, J., He, T.-F., Mansour, A. G., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141683 · Cited by 78
Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers
Zhang, H., Cao, K., Xiang, J., Zhang, M., Zhu, M., & Xi, Q. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216345 · Cited by 71
Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer
Tong, C. C. L., Kao, J., & Sikora, A. G. (2012) · Immunologic Research · doi:10.1007/s12026-012-8306-6 · Cited by 71
Hu, X., Bardhan, K., Paschall, A. V., Yang, D., Waller, J. L., Park, M. A., Nayak-Kapoor, A., Samuel, T. A., Abrams, S. I., & Liu, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434530 · Cited by 71
Sinha, P., & Ostrand‐Rosenberg, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1470-2 · Cited by 73
Tumour‐induced immune suppression: role of inflammatory mediators released by myelomonocytic cells
Mao, Y., Poschke, I., & Kiessling, R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12229 · Cited by 65
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 79
Hampering Immune Suppressors: Therapeutic Targeting of Myeloid-Derived Suppressor Cells in Cancer
Albeituni, S., Ding, C., & Yan, J. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000006 · Cited by 71
Myeloid cells in tumor inflammation
Schmid, M. C., & Varner, J. A. (2012) · Vascular Cell · doi:10.1186/2045-824x-4-14 · Cited by 65
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Srivastava, N., Usmani, S. S., Subbarayan, R., Saini, R., & Pandey, P. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1199105 · Cited by 72
Jayaraman, P., Parikh, F., Newton, J. M., Hanoteau, A., Rivas, C. H., Krupar, R., Rajapakshe, K., Pathak, R. R., Kanthaswamy, K., MacLaren, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490853 · Cited by 66
Hammami, A., Charpentier, T., Smans, M., & Stäger, S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004938 · Cited by 64
Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis
Català‐Moll, F., Ferreté-Bonastre, A. G., Godoy‐Tena, G., Morante-Palacios, O., Ciudad, L., Barberà, L., Fondelli, F., Martínez-Cáceres, E. M., Rodríguez‐Ubreva, J., Li, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110244 · Cited by 66
Zetrini, A., Lip, H., Abbasi, A. Z., Alradwan, I. A., Ahmed, T., He, C., Henderson, J. T., Rauth, A. M., & Wu, X. Y. (2023) · Research · doi:10.34133/research.0247 · Cited by 73
Guédez, L., Jensen-Taubman, S., Bourboulia, D., Kwityn, C., Wei, B., Caterina, J. J., & Stetler‐Stevenson, W. G. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182619c8e · Cited by 64
Hypoxia-inducible factors as key regulators of tumor inflammation
Mamlouk, S., & Wielockx, B. (2013) · International Journal of Cancer · doi:10.1002/ijc.27901 · Cited by 61
Lakshmanachetty, S., Cruz, J. C., Hoffmeyer, E., Cole, A. P., & Mitra, S. S. (2021) · Cells · doi:10.3390/cells10040893 · Cited by 69
Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma
Xu, S., Tang, L., Liu, Z., Luo, C., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731048 · Cited by 76
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting
Kumar, V. (2018) · Inflammation · doi:10.1007/s10753-018-0939-8 · Cited by 71
Eckert, F., Zwirner, K., Boeke, S., Thorwarth, D., Zips, D., & Huber, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00407 · Cited by 62
Carbohydrate and Amino Acid Metabolism as Hallmarks for Innate Immune Cell Activation and Function
Zhao, H., Raines, L. N., & Huang, S. C. (2020) · Cells · doi:10.3390/cells9030562 · Cited by 67
Wang, S., Zhao, X., Wu, S., Cui, D., & Xu, Z. (2023) · Biomarker Research · doi:10.1186/s40364-023-00475-8 · Cited by 62
Macrophages as Promising Carriers for Nanoparticle Delivery in Anticancer Therapy
Wróblewska, A., Szczygieł, A., Szermer-Olearnik, B., & Pajtasz‐Piasecka, E. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s421173 · Cited by 68
Shi, Z., Hu, C., Zheng, X., Sun, C., & Li, Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00519-1 · Cited by 75
Huang, A., Sun, Z., Hong, H., Yang, Y., Chen, J., Gao, Z., & Gu, J. F. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05391-5 · Cited by 79
Guan, Q., Moreno, S., Qing, G., Weiss, C. R., Lü, L., Bernstein, C. N., Warrington, R., Ma, Y., & Peng, Z. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0113050 · Cited by 60
O'Kane, G. M., Connor, A. A., & Gallinger, S. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.007 · Cited by 67
Contribution of hypoxia inducible factor-1 during viral infections
Reyes, A., Corrales, N., Gálvez, N. M. S., Bueno, S. M., Kalergis, A. M., & González, P. A. (2020) · Virulence · doi:10.1080/21505594.2020.1836904 · Cited by 59
Transcription factors in myeloid-derived suppressor cell recruitment and function
Sonda, N., Chioda, M., Zilio, S., Simonato, F., & Bronte, V. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.006 · Cited by 65
Mendoza, E. N., Ciriolo, M. R., & Ciccarone, F. (2025) · Antioxidants · doi:10.3390/antiox14010094 · Cited by 73
Atanasov, G., Dietel, C., Feldbrügge, L., Benzing, C., Krenzien, F., Brandl, A., Mann, E., Englisch, J. P., Schierle, K., Robson, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331806 · Cited by 61
Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives
Koinis, F., Xagara, A., Chantzara, E., Leontopoulou, V., Aidarinis, C., & Kotsakis, A. P. (2021) · Cells · doi:10.3390/cells11010020 · Cited by 70
Modulating tumor physical microenvironment for fueling CAR-T cell therapy
Luo, Z. Y., Yao, X., Li, M., Fang, D., Fei, Y., Cheng, Z., Xu, Y., & Zhu, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114301 · Cited by 62
Function of reactive oxygen species in myeloid-derived suppressor cells
Huang, J., Zhao, Y., Zhao, K., Yin, K., & Wang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226443 · Cited by 70
Selective class IIa HDAC inhibitors: myth or reality
Giorgio, E. D., Gagliostro, E., & Brancolini, C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1727-8 · Cited by 68
Chemokines, Costimulatory Molecules and Fusion Proteins for the Immunotherapy of Solid Tumors
Lechner, M. G., Russell, S. M., Bass, R. S., & Epstein, A. L. (2011) · Immunotherapy · doi:10.2217/imt.11.115 · Cited by 58
State-of-the-art of regulatory dendritic cells in cancer
Conejo-Garcia, J. R., Rutkowski, M. R., & Cubillos-Ruiz, J. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.003 · Cited by 58
Domingo-Gonzalez, R., Das, S., Griffiths, K., Ahmed, M., Bambousková, M., Gopal, R., Gondi, S., Muñoz-Torrico, M. V., Salazar-Lezama, M. Á., Cruz‐Lagunas, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92973 · Cited by 66
MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages
Curtale, G. (2018) · Cells · doi:10.3390/cells7020012 · Cited by 62
Interactions among myeloid regulatory cells in cancer
Umansky, V., Adema, G. J., Baran, J., Brandau, S., Ginderachter, J. A. V., Hu, X., Jabłońska, J., Mojsilović, S. B., Papadaki, H. Α., de Coaña, Y. P., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2200-6 · Cited by 64
Jamieson, S. M. F., Tsai, P., Kondratyev, M. K., Budhani, P., Liu, A. J., Senzer, N. N., Chiorean, E. G., Jalal, S. I., Nemunaitis, J. J., Kee, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122204 · Cited by 61
Fujimura, T., & Aiba, S. (2020) · Biomolecules · doi:10.3390/biom10081087 · Cited by 61
Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth
Nemeth, Z., Csizmadia, E., Vikstrom, L., Li, M., Bisht, K., Feizi, A., Otterbein, S., Zuckerbraun, B., Costa, D. B., Pandolfi, P. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8081 · Cited by 57
Deng, Y., Yang, J., Luo, F., Qian, J., Liu, R., Zhang, D., Yu, H., & Chu, Y. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2177-1 · Cited by 62
Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression
Sica, A., Guarneri, V., & Gennari, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.197 · Cited by 58
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Aggen, D. H., Drake, C. G., & Rini, B. I. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3323 · Cited by 60
Liu, Y., Xu, D., Liu, Y., Zheng, X. W., Zang, J., Ye, W., Zhao, Y., He, R., Ruan, S., Zhang, T., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121516 · Cited by 58
Basso, D., Fogar, P., Falconi, M., Fadi, E., Sperti, C., Frasson, C., Greco, E., Tamburrino, D., Teolato, S., Moz, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054824 · Cited by 57
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments
Chan, T., Wiltrout, R. H., & Weiss, J. M. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.12.024 · Cited by 57
Defective TGF-β Signaling in Bone Marrow–Derived Cells Prevents Hedgehog-Induced Skin Tumors
Fan, Q., Gu, D., Liu, H., Yang, L., Zhang, X., Yöder, M. C., Kaplan, M. H., & Xie, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2134-t · Cited by 58
The metabolic axis of macrophage and immune cell polarization
Hobson-Gutierrez, S. A., & Carmona-Fontaine, C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034462 · Cited by 56
Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 59
Dar, A. A., Patil, R. S., Pradhan, T. N., Chaukar, D. A., Dcruz, A. K., & Chiplunkar, S. V. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02523-w · Cited by 60
Rutkowski, M. R., Svoronos, N., Perales‐Puchalt, A., & Conejo-Garcia, J. R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.011 · Cited by 64
Hypoxia and hypoxia-inducible factors in myeloid cell-driven host defense and tissue homeostasis
Jantsch, J., & Schödel, J. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.009 · Cited by 46
Chiarella, P., Bruzzo, J., Meiss, R. P., & Ruggiero, R. A. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.021 · Cited by 57
Zhu, J., Huang, X., & Yang, Y. (2012) · Journal of Virology · doi:10.1128/jvi.01595-12 · Cited by 55
Moses, K., Klein, J. C., Männ, L., Grüneboom, A., Gunzer, M., & Brandau, S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.1hi0715-289r · Cited by 58
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 60
HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer
Cheng, K. J., Alshawsh, M. A., Mohamed, E. H. M., Thavagnanam, S., Sinniah, A., & Ibrahim, Z. A. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00477-5 · Cited by 63
Chang, W. H., & Lai, A. G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.011 · Cited by 55
Metabolism of Innate Immune Cells in Cancer
Talty, R., & Olino, K. L. (2021) · Cancers · doi:10.3390/cancers13040904 · Cited by 60
Stoltzfus, C. R., Sivakumar, R., Kunz, L., Olin, B. E., Menietti, E., Speziale, D., Adelfio, R., Bacac, M., Colombetti, S., Perro, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726492 · Cited by 56
Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy
Li, Q., & Xiang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00776-4 · Cited by 59
Targeting hypoxia in solid and haematological malignancies
Harris, B., Saleem, S., Cook, N., & Searle, E. J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02522-y · Cited by 61
FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion
Zhao, Z., Qin, J., Qian, Y., Huang, C., Liu, X., Wang, N., Li, L., Chao, Y., Tan, B., Zhang, N., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01529-6 · Cited by 65
Yu, F., Shi, Y. Q., Wang, J., Li, J., Fan, D., & Ai, W. (2013) · International Journal of Cancer · doi:10.1002/ijc.28302 · Cited by 57
Tumor Microenvironmental Conversion of Natural Killer Cells into Myeloid-Derived Suppressor Cells
Park, Y.-J., Song, B., Kim, Y.-S., Kim, E., Lee, J.-M., Lee, G.-E., Kim, J., Kim, Y., Chang, W., & Kang, C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0545 · Cited by 63
Hock, B. D., Mackenzie, K. A., Cross, N., Taylor, K. G., Currie, M. J., Robinson, B. A., Simcock, J., & McKenzie, J. L. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr264 · Cited by 54
Xu, Z., Ji, J., Xu, J., Li, D., Shi, G., Liu, F., Ding, L., Ren, J., Dou, H., Wang, T., et al. (2017) · FEBS Journal · doi:10.1111/febs.14133 · Cited by 58
Hypoxic Signalling in Tumour Stroma
Laitala, A., & Erler, J. T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00189 · Cited by 58
Trillo-Tinoco, J., Sierra, R. A., Mohamed, E. T., Cao, Y. W., Pulido, Á. D. M., Gilvary, D. L., Anadon, C. M., Costich, T. L., Wei, S., Flores, E. R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0880 · Cited by 55
Tian, X., Zheng, Y., Yin, K., Ma, J., Tian, J., Zhang, Y., Mao, L., Xu, H., & Wang, S. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0595 · Cited by 58
Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia
Hanna, B. S., Öztürk, S., & Seiffert, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.014 · Cited by 56
The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT
Moon, E. J., Petersson, K., & Olcina, M. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1988178 · Cited by 63
Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership
Bergerud, K. B., Berkseth, M., Pardoll, D. M., Ganguly, S., Kleinberg, L. R., Lawrence, J., Odde, D. J., Largaespada, D. A., Terezakis, S. A., & Sloan, L. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.11.050 · Cited by 66
Wang, Q., Yu, M., & Zhang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440830 · Cited by 68
Hammami, A., Abidin, B. M., Charpentier, T., Fabié, A., Duguay, A.-P., Heinonen, K. M., & Stäger, S. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006616 · Cited by 59
The innate immune architecture of lung tumors and its implication in disease progression
Milette, S., Fiset, P., Walsh, L. A., Spicer, J. D., & Quail, D. F. (2019) · The Journal of Pathology · doi:10.1002/path.5241 · Cited by 58
What Can Ecology Teach Us About Cancer?
Kareva, I. (2011) · Translational Oncology · doi:10.1593/tlo.11154 · Cited by 58
Schouppe, E., Overmeire, E. V., Laoui, D., Keirsse, J., & Ginderachter, J. A. V. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.07.003 · Cited by 51
l-glutamine is a key parameter in the immunosuppression phenomenon
Hammami, I., Chen, J., Bronte, V., Crescenzo, G. D., & Jolicœur, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.139 · Cited by 53
Zhang, G., Huang, H., Zhu, Y., Yu, G., Gao, X., Xu, Y., Liu, C., Hou, J., & Zhang, X. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.977164 · Cited by 58
The Role of Myeloid-Derived Suppressor Cells in Viral Infection
O’Connor, M. A., Rastad, J. L., & Green, W. R. (2017) · Viral Immunology · doi:10.1089/vim.2016.0125 · Cited by 55
Köstlin‐Gille, N., Dietz, S., Schwarz, J., Spring, B., Pauluschke‐Fröhlich, J., Poets, C. F., & Gille, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00161 · Cited by 62
Giatromanolaki, A. N., Harris, A. L., Banham, A. H., Contrafouris, C., & Koukourakis, M. I. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0756-3 · Cited by 54
Underlying mechanisms and drug intervention strategies for the tumour microenvironment
Li, H., Zhou, L., Zhou, J., Li, Q., & Ji, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01893-y · Cited by 55
Bioresponsive Immunotherapeutic Materials
Han, J., Sheng, T., Zhang, Y., Cheng, H., Gao, J., Yu, J., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202209778 · Cited by 62
Metadata
- Authors
- Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-09-27
- Volume
- 207
- Issue
- 11
- Pages
- 2439-2453
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2964584
- OpenAlex
- W2109424201
- Semantic Scholar
- 77cf3cf3976e026979d2b7acf9b04119740a45f1
- Cited by
- 1,173
- References
- 56
- Citations by year
- 2026: 69 · 2025: 73 · 2024: 69 · 2023: 92 · 2022: 80 · 2021: 109 · 2020: 93 · 2019: 62 · 2018: 83 · 2017: 62 · 2016: 69 · 2015: 51 · 2014: 70 · 2013: 76 · 2012: 61
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute (CA84488, R01CA084488, R01CA103921, R01CA136828, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- myeloid-derived suppressor cells, HIF-1α, tumor microenvironment, hypoxia, tumor-associated macrophages, T cell suppression, arginase-1, inducible nitric oxide synthase, NADPH oxidase, reactive oxygen species, MDSC differentiation, immunosuppression
- MeSH terms
- Aged, Animals, Antigens, Neoplasm, Arginase, Cell Differentiation, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Middle Aged, Neoplasms, Cell Hypoxia, CD8-Positive T-Lymphocytes, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.